To test whether fascin inhibitors could be used as a maintenance therapy to slow the process of tumor relapse, we administered NP-G2-044 after the surgical removal of primary tumors and systematic chemotherapy, and then examined the metastatic recurrence of breast tumors. This evidence concerns the gene FSCN1 and breast neoplasm.